ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2018
Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
77 citing papers in PubMed, 2 syntheses or guidelines pooled it, 154 citations in OpenAlex.
- Modulating the endocannabinoid system in alcohol use disorder: A translational systematic review and meta-analysis of preclinical and human studies.Molecular psychiatry · 2026Pooled it
- Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review.Alcoholism, clinical and experimental research · 2019Pooled it
- Effects of cannabidiol on risky decision-making and autonomic function in alcohol use disorder.Alcohol and alcoholism (Oxford, Oxfordshire) · 2026Trial
- Acute Effects of Cannabis on Alcohol Craving and Consumption: A Randomized Controlled Crossover Trial.The American journal of psychiatry · 2026Trial
- The neural and psychophysiological effects of cannabidiol in youth with alcohol use disorder: A randomized controlled clinical trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Trial
- Acute cannabidiol administration reduces alcohol craving and cue-induced nucleus accumbens activation in individuals with alcohol use disorder: the double-blind randomized controlled ICONIC trial.Molecular psychiatry · 2025Trial
- Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: a randomized placebo-controlled trial.Addiction (Abingdon, England) · 2021Trial
- Cannabidiol and Alcohol Use Disorders: An Updated Review of Therapeutic Potential.Alcohol, clinical & experimental research · 2026Review
- Cannabidiol and neural correlates of threat anticipation in alcohol use disorder.Psychopharmacology · 2026Article
- Safety of Co-Administered Cannabidiol (CBD) and alcohol: a Phase I study.Journal of cannabis research · 2026Article
- Brain CB2 receptor: a new target in medication development for treating opioid use disorder in rodents.Molecular psychiatry · 2026Article
- Cannabidiol as a treatment for cocaine use disorder: a scoping review.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Effect of cannabinol, tetrahydrocannabivarin and cannabidiol on voluntary alcohol consumption.Alcohol and alcoholism (Oxford, Oxfordshire) · 2026Article
- Sex and dose-dependent effects of cannabidiol on cocaine consumption in mice.Translational psychiatry · 2026Article
- Cannabidiol mitigates alcohol dependence and withdrawal with neuroprotective effects in the basolateral amygdala and striatum.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Cannabinoid-based Pharmacology for the Management of Substance Use Disorders.Current topics in behavioral neurosciences · 2026Review
- Cannabidiol: Pharmaceutical formulations and biomedical applications.Iranian journal of basic medical sciences · 2026Review
- Recruitment of Neuronal Populations in the Paraventricular Thalamus of Alcohol-Seeking Rats With Withdrawal-Related Learning Experience.Biological psychiatry global open science · 2025Article
- High hopes, hard realities: cannabidiol shows no acute effects in youth with alcohol use disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Article
17 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
Cannabidiol (CBD), the major non-psychoactive constituent of Cannabis sativa, has received attention for therapeutic potential in treating neurologic and psychiatric disorders. Recently, CBD has also been explored for potential in treating drug addiction. Substance use disorders are chronically relapsing conditions and relapse risk persists for multiple reasons including craving induced by drug contexts, susceptibility to stress, elevated anxiety, and impaired impulse control. Here, we evaluated the "anti-relapse" potential of a transdermal CBD preparation in animal models of drug seeking, anxiety and impulsivity. Rats with alcohol or cocaine self-administration histories received transdermal CBD at 24 h intervals for 7 days and were tested for context and stress-induced reinstatement, as well as experimental anxiety on the elevated plus maze. Effects on impulsive behavior were established using a delay-discounting task following recovery from a 7-day dependence-inducing alcohol intoxication regimen. CBD attenuated context-induced and stress-induced drug seeking without tolerance, sedative effects, or interference with normal motivated behavior. Following treatment termination, reinstatement remained attenuated up to ≈5 months although plasma and brain CBD levels remained detectable only for 3 days. CBD also reduced experimental anxiety and prevented the development of high impulsivity in rats with an alcohol dependence history. The results provide proof of principle supporting potential of CBD in relapse prevention along two dimensions: beneficial actions across several vulnerability states and long-lasting effects with only brief treatment. The findings also inform the ongoing medical marijuana debate concerning medical benefits of non-psychoactive cannabinoids and their promise for development and use as therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.